about
Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009)Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivirClinical Outcome of Novel H1N1 (Swine Flu)-Infected Patients During 2009 Pandemic at Tertiary Referral Hospital in Western India.Content analysis of press coverage during the H1N1 influenza pandemic in Germany 2009-2010.Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza.Diagnostic approach for the differentiation of the pandemic influenza A(H1N1)v virus from recent human influenza viruses by real-time PCRPopulation-based surveillance for 2009 pandemic influenza A (H1N1) virus in Guatemala, 2009Differences in the epidemiological characteristics and clinical outcomes of pandemic (H1N1) 2009 influenza, compared with seasonal influenzaThe first wave of pandemic influenza (H1N1) 2009 in Germany: from initiation to acceleration.Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from interpandemic community-acquired pneumonia in adults.Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literatureSystematic review of clinical and epidemiological features of the pandemic influenza A (H1N1) 2009Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in German adult population in pre- and post-pandemic period.Determinants of the spatiotemporal dynamics of the 2009 H1N1 pandemic in Europe: implications for real-time modellingProspective hospital-based case-control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009-2010 using matched hospital and test-negative controlsInterleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection.Pandemic influenza A(H1)pdm09 in hospitals and intensive care units - results from a new hospital surveillance, Germany 2009/2010Targeted vs. systematic early antiviral treatment against A(H1N1)v influenza with neuraminidase inhibitors in patients with influenza-like symptoms: clinical and economic impactAcceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the Cologne-Bonn cohortHeterogeneous length of stay of hosts' movements and spatial epidemic spread.Confirmation diagnosis of influenza A(H1N1)2009 by Belgian sentinel laboratories during the epidemic phase.
P2860
Q24632365-F8EFE029-725F-40CC-B0EF-A2824EEFCEB3Q30227249-72D8EDAD-3BC5-42BE-97C3-7A1B5A1254ADQ30353760-DD4E88DE-6F03-44DF-B48A-B5B1419EF1A7Q30373879-14672335-5638-4D36-91CD-E35B19107DC0Q30383368-0FB8A8BC-E540-4931-A63A-46A73373B67BQ30387864-92E62703-7FF6-466A-B986-1216B90C53DBQ30388373-FCE8375B-0E92-4909-BAE9-C56B195E39E3Q30389644-C40E650C-4F58-41C5-95A1-8642182D717EQ30390035-5579592D-A6AC-4ECA-B702-18D836E8751DQ30398779-F8474CFE-9A83-4CEF-B5B1-8C84EE440830Q30399278-9147C9A3-578F-47A6-A404-C9A736A4136EQ30401654-DCDFB663-F757-4804-9736-0476CF6C0FCEQ30404184-3CAFB09A-F3D3-4FB5-B505-60817F16AE90Q30407922-77B843FA-D3D4-40CA-9D97-23DDEFBF7647Q30417417-BC6C1738-3BFC-4B15-AC50-B916D55D3C75Q30417745-7050C696-EA30-4424-9848-76450389D25CQ30419101-95F0515D-1A6C-4D3A-ACB9-D06B820568B1Q33520449-35A52063-0C71-47C9-9792-0137C7271E7AQ35959213-53F91C41-AB74-4798-9E3F-C66107BFF3D0Q42122563-54ADCA99-CD4C-426C-92E8-770CF9D82553Q55504950-FDB7A9AB-BFF8-4EEC-9B97-032ED68CAEC6
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Influenza A(H1N1)v in Germany: the first 10,000 cases.
@en
Influenza A(H1N1)v in Germany: the first 10,000 cases.
@nl
type
label
Influenza A(H1N1)v in Germany: the first 10,000 cases.
@en
Influenza A(H1N1)v in Germany: the first 10,000 cases.
@nl
prefLabel
Influenza A(H1N1)v in Germany: the first 10,000 cases.
@en
Influenza A(H1N1)v in Germany: the first 10,000 cases.
@nl
P2093
P1433
P1476
Influenza A(H1N1)v in Germany: the first 10,000 cases
@en
P2093
Andreas Gilsdorf
Gabriele Poggensee
Working Group Pandemic Influenza A(H1N1)v
P304
P356
10.2807/ESE.14.34.19318-EN
P577
2009-08-27T00:00:00Z